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Background: Elevated Glasgow Prognostic Score (GPS) has been related to poor prognosis in patients with
hepatocellular carcinoma (HCC) undergoing surgical resection or receiving sorafenib. The aim of this study was to
investigate the prognostic value of GPS in patients with various stages of the disease and with different liver
functional status.
Methods: One hundred and fifty patients with newly diagnosed HCC were prospectively evaluated. Patients were
divided according to their GPS scores. Univariate and multivariate analyses were performed to identify
clinicopathological variables associated with overall survival; the identified variables were then compared with those
of other validated staging systems.
Results: Elevated GPS were associated with increased asparate aminotransferase (P<0.0001), total bilirubin (P<0.0001),
decreased albumin (P<0.0001), α-fetoprotein (P=0.008), larger tumor diameter (P=0.003), tumor number (P=0.041),
vascular invasion (P=0.0002), extra hepatic metastasis (P=0.02), higher Child-Pugh scores (P<0.0001), and higher Cancer
Liver Italian Program scores (P<0.0001). On multivariate analysis, the elevated GPS was independently associated with
worse overall survival.
Conclusions: Our results demonstrate that the GPS can serve as an independent marker of poor prognosis in patients
with HCC in various stages of disease and different liver functional status.
Keywords: The Glasgow Prognostic Score, Hepatocellular carcinoma, Prognostic markerBackground
Hepatocellular carcinoma (HCC) is the seventh most
common cancer worldwide, and the third leading cause
of cancer-related deaths [1]. In contrast to other cancers,
prognosis and treatment options for patients with HCC
depend not only on the tumor progression but also on the
extent of liver dysfunction [2].
A number of staging systems for HCC have been pro-
posed including Barcelona Clinic Liver Cancer (BCLC) [3],
Cancer Liver Italian Program (CLIP) [4], and Japanese Inte-
grated Staging Score (JIS) systems [5]. However, a world-
wide consensus has not been established on which of the* Correspondence: aki.kino@jikei.ac.jp
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reproduction in any medium, provided the orsystems is most accurate for staging and predicting progno-
sis of HCC.
In addition, accumulating evidence indicates that the
Glasgow Prognostic Score (GPS) system based on inflam-
mation criteria and including only serum C-reactive protein
(CRP) and albumin, is a reliant and practical scoring system
for outcome prognostication in patients with advanced can-
cer, such as colorectal cancer [6,7], esophageal cancer [8],
gastric cancer [9], pancreatic cancer [10], and lung cancer
[11]. Recently, Proctor et al. have shown that modified GPS
(mGPS) is a powerful prognostic factor independent of
tumor site in patients with cancer and is superior to GPS
[12]. It was based on the observation that hypoalbuminae-
mia without an elevated CRP concentration was rare and
that hypoalbuminaemia on its own was not associated with
poor survival [13].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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demonstrated that GPS can serve as a predictor of over-
all survival but the patients enrolled in their study
included only those who underwent surgical resection
[14]. Morimoto et al. also have shown that elevated GPS
has a significant prognostic value in patients with advanced
HCC, but the study was limited to patients treated with
sorafenib [15]. Thus, although the studies addressed valid-
ity of GPS in HCC patients, they did not provide sufficient
evidence whether elevated GPS is prognostically efficient
in all HCC patients, i.e. with different stages of the disease
and different liver functional statuses, and did not clarify
which of the GPS (original or modified) is more suitable
in regard to their discriminating ability and monoton-
icity of gradients.
In the present study, we evaluated usefulness of both
GPS and mGPS in prediction of overall survival in patients
with HCC in various stages of the disease and different
liver functional statuses, and compared obtained findings
with those of other validated staging systems.Methods
Patients
Two hundred and eight consecutive patients with newly
diagnosed HCC treated at the Department of Gastroenter-
ology and Hepatology, Jikei University Daisan Hospital,
between January 2005 and October 2011 were prospect-
ively enrolled and their medical records were retrospect-
ively reviewed. Twenty-three patients were lost to follow
up. Thirty-five patients, whose entire set of laboratory data
was not available, were excluded from the study. Patients
who showed clinical evidence of infection or other in-
flammatory conditions were also excluded. In total, 150
patients with HCC were finally enrolled and evaluated;
all were included in our previous study [16].
The diagnosis of HCC was pathologically confirmed or
was based on findings obtained by 4-phase multidetector
computed tomography (CT) or dynamic contrast-enhanced
magnetic resonance imaging (MRI). Definitive diagnosis
was made when a typical hallmark of HCC (hypervascu-
lar area in the arterial phase and washout area in the
portal venous or delayed phases) [17] was observed in
the contrast-enhanced images. Tumor-related variables
such as the maximal tumor diameter, number, vascular
invasion, and extra hepatic metastases were evaluated with
the same imaging techniques. The clinical stage (TNM
classification) was determined according to the Liver
Cancer Study Group of Japan [18].
This study complied with the standards of the Helsinki
Declaration and current ethical guidelines and was approved
by the institutional ethical board of the Jikei University
Daisan Hospital. Written informed consent for participa-
tion in the study was not obtained from patients, becausethis study did not report on a clinical trial, and the data
ware retrospective in nature and analyzed anonymously.
GPS and other variables
Blood samples were obtained before commencement of
treatment for CRP, serum albumin, asparate aminotrans-
ferase (AST), alanine aminotransferase (ALT), total biliru-
bin (T-Bil), white blood cell count (WBC), platelet count
(Plt), prothrombin time (PT), indocyanine green dye re-
tention rate at 15 minutes (ICG), and α-fetoprotein levels
(AFP). The CLIP score, JIS score, BCLC were calculated
based on obtained results and imaging data.
GPS and mGPS were described previously. Briefly, in
GPS, patients with both an elevated CRP level (>1.0 mg/dl)
and hypoalbuminemia (<3.5 g/dl) were allocated a score of
2, patients with only one of these biochemical abnormal-
ities were allocated a score of 1, and patients with neither
of these abnormalities were allocated a score of 0 [19]. The
mGPS was calculated also with CRP and albumin
values as follows: patients with both an elevated CRP level
(>1.0 mg/dl) and hypoalbuminemia (<3.5 g/dl) were allo-
cated a score of 2, patients with an elevated CRP level
(>1.0 mg/dl) only were allocated a score of 1, and patients
with a normal CRP level (≤ 1.0 mg/dl) and any albumin
concentration were allocated a score of 0 [20].
Treatment and patient’s follow-up
Criteria of surgical resection were: a solitary lesion, Child-
Pugh grade A, no main portal vein trunk involvement or
no distant metastasis. Radiofrequency ablation (RFA) or
percutaneous ethanol injection (PEI) was performed in
patients with lesions <3 cm in size and <3 in number.
Transcatehter arterial chemoembolization (TACE) or
lipiodol- transcatehter arterial infusion (TAI) was per-
formed in patients with multiple lesions of more than 4 in
number or larger than 3 cm in size. Systemic chemother-
apy or targeted therapy including sorafenib was carried
out in patients with distant metastasis but preserved liver
function. For patients with Child-Pugh grade C or distant
metastasis, only best supportive care (BSC) was provided.
We presumed that it is of importance to evaluate prog-
nosis in patients with curative or non-curative treat-
ment separately in an attempt to minimize the impact
of different treatment modalities in the process of evalu-
ating the prognostic model. Therefore, in this study,
according to the current EASL-EORTC clinical practice
guidelines [17], a curative treatment was defined as ag-
gressive treatment, including surgical resection, RFA, PEI.
By contrast, a non-curative treatment was defined as other
palliative treatment (TACE, TAI, systemic chemotherapy,
sorafenib or BSC).
After the initial treatment phase, patients were carefully
followed. Serum AFP was measured once every month.
Ultrasonography and dynamic CT were performed every 3
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percutaneous biopsy was performed in patients with
suspected tumor recurrence. The start date of follow-up
period was the date of initial HCC diagnosis. The end
of the follow-up was set as the time of last follow-up
(October 2011) or death.
Statistical analysis
Continuous variables were presented as median and
range. Categorical variables were presented numbers and
percentages. Comparison between the groups was per-
formed with the Kruskal-Wallis test for continuous and
ordinal variables and with the chi-square test for cat-
egorical variables. The overall survival rates were calcu-
lated using the Kaplan-Meier method and differences in
the survival rates between the groups were compared by
the log-rank test. To compare the prognostic ability of
each staging systems, the linear χ2 test (for measuring
both discriminatory ability and monotonicity of theFigure 1 Histogram indicating the distribution of CRP and Albumin ingradient across categories) and the −2 log likelihood
(for measuring homogeneity) were used [21,22]. Both
tests were performed using values calculated from the
Cox-proportional hazard model. Generally, more ac-
curate staging systems showed higher linear χ2 values
and lower −2 log likelihoods. To evaluate the discrim-
inatory ability of each staging systems, a receiver oper-
ating characteristics (ROC) curves was generated and
the areas under the curve were measured. For assess-
ment of prognostic factors, univariate and multivariate
analysis were performed using the Cox-proportional
hazard model. Variables that proved to be significant in
the univariate analysis were tested subsequently with
multivariate Cox-proportional hazard model. The for-
ward selection method was used for multivariate Cox-
proportional analysis. A P-value <0.05 was considered
significant. All statistical analyses were performed using
IBM SPSS Statistics software v.19.0 (IBM SPSS Inc.,
Chicago, IL, USA).the GPS groups (a), mGPS groups (b).
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Patient characteristics
The median age of patients was 72 (range 43–91) years.
One hundred and six (70.7%) patients were males and
44 (29.3%) patients were females. Eighty four (56%) patients
were positive for antibodies to hepatitis C virus (anti-
HCV), 20 (13.3%) patients were positive for hepatitis B
surface antigen (HBs Ag). Diagnosis of HCC was con-
firmed histologically in 31 (20.7%) patients, whereas in
other patients it was based on imaging data. Surgical re-
section was performed in 9 (6%) patients, TACE or RFA
were carried out in 134 (89.3%) patients. One (0.7%) pa-
tient received systemic therapy. The remaining 6 (4%)
patients received BSC. Seventy seven (51.3%) patients
received curative treatment and 73 (48.7%) patients
received non-curative treatment.
Thirty one (20.7%) patients showed an elevated CRP
level (>1.0 g/dl) and 58 (38.7%) patients had hypoalbu-
minemia (<3.5 g/dl). Eighty one (54%) patients were allo-
cated a GPS of 0, 49 (32.7%) patients were allocated a
GPS of 1, and 20 (13.3%) patients were allocated a GPS
of 2, respectively. By contrast, 119 (79.3%) patients were
allocated an mGPS of 0, 11 (7.3%) patients were allocatedTable 1 Clinicopahtological characteristics of patients groupe
Variable GPS 0 (n = 81)
Age (years) 71 (43–91)
Sex (male/female) 57/23
HBsAg positive (%) 8(10)
HCVAb positive (%) 52 (65)
AST (IU/l) 50 (18–148)
ALT (IU/l) 39 (10–202)
Total serum bilirubin (mg/dl) 0.7 (0.3-1.9)
Albumin (g/dl) 3.9 (3.5-5)
CRP (mg/dl) 0.1 (0.1-0.8)
WBC (cells/mm3) 5300 (2500–14800)
Platelet count (104/mm3) 14.2 (2.9-29.5)
Prothrombin time (%) 85 (38–100)
α-fetoprotein (ng/ml) 17 (1.9-59597)
Child-Pugh grade (A/B/C) 78/2/0
CLIP score (0/1/2/3≧) 35/31/10/4
JIS score (0/1/2/3≧) 17/32/27/4
BCLC score (0/A/B/C,D) 16/41/19/4
Tumor stage (І,ІІ,ІІІ,ІV) 16/34/28/2
Maximal tumor diameter (mm) 28 (7–90)
Tumor number (solitary/multiple) 45/35
Vascular invasion (absent/present) 77/3
Extrahepatic metastasis (absent/present) 79/1
Abbreviaions: HBsAg = hepatitis B surface antigen; HCVAb = hepatitis C antibody; AS
CRP = C-reactive protein; WBC = white blood cell count; ICG = indocyanine green dy
JIS = Japan Integrated Staging score; BCLC = Barcelona Clinic Liver Cancer; GPS = Glaan mGPS of 1, and 20 (13.3%) patients were allocated an
mGPS of 2. A histogram indicating the distribution of
CRP and albumin in the GPS and m GPS groups is pre-
sented in Figure 1a, b.
Baseline characteristics of patients grouped according
to GPS/mGPS allocation are shown in Table 1, 2. There
were significant differences between the GPS groups in
age (P=0.048), AST (P<0.0001), ALT (P=0.017), T-Bil
(P<0.0001), PT (P = 0.022), AFP (P=0.008), maximal
tumor diameter (P=0.003), tumor number (P=0.041),
frequency of vascular invasion (P=0.0002), and frequency of
extra hepatic metastasis (P=0.02). An elevated GPS was also
associated with higher Child-Pugh scores (P<0.0001), higher
CLIP scores (P<0.0001), higher JIS scores (P<0.0001), higher
BCLC scores (P<0.0001), and higher TNM classification
(P<0.0001).
Comparison of the prognostic ability for overall survival
The median follow-up duration was 18 (range 1–80) months.
At the end of the follow-up period, 77 (51.3%) patients
were alive, and 73 (48.7%) patients died. The most com-
mon cause of death was tumor progression or hepatic
failure (n = 60 , 82.2%), followed by other malignanciesd according to GPS
GPS 1 (n = 49) GPS 2 (n = 20) P-value
74 (54–86) 72 (51–79) 0.05
33/16 16/4 0.57
4 (8.2) 5 (25) 0.12
24 (49) 7 (35) 0.03
58 (14–240) 113 (13–384) <0.0001
39 (12–190) 78 (8–157) 0.02
1 (0.3-6.1) 1.6 (0.3-8.3) <0.0001
3.2 (2.1-4.6) 3.2 (2.2-3.4) <0.0001
0.3 (0.1-2.9) 2.6 (1.1-18.8) <0.0001
5100 (1800–14900) 5800 (3900–12400) 0.13
11.6 (1.8-42.1) 17.3 (8.7-44.3) 0.07
78 (41–100) 77 (45–97) 0.02










T = aspartate aminotransferase; ALT = alanine aminotransferase.
e retention rate at 15 minutes; CLIP = Cancer of the Liver Italian Program.
sgow Prognostic Score.
Table 2 Clinicopahtological characteristics of patients grouped according to mGPS
Variable mGPS 0 (n = 119) mGPS 1 (n = 11) mGPS 2 (n = 20) P-value
Age (years) 72 (43–91) 74 (64–82) 72 (51–79) 0.14
Sex (male/female) 80/39 10/1 16/4 0.16
HBsAg positive (%) 12 (10) 2 (18) 5 (25) 0.15
HCVAb positive (%) 76 (64) 1 (9) 7 (35) 0
AST (IU/l) 53 (14–240) 56 (17–238) 113 (13–384) <0.0001
ALT (IU/l) 39 (10–202) 53 (14–190) 78 (8–157) 0.02
Total serum bilirubin (mg/dl) 0.8 (0.3-3.1) 0.7 (0.3-6.1) 1.6 (0.3-8.3) 0
Albumin (g/dl) 3.7 (2.1-5) 3.9 (3.5-4.6) 3.2 (2.2-3.4) <0.0001
CRP (mg/dl) 0.1 (0.1-0.9) 1.5 (1.1-2.9) 2.6 (1.1-18.8) <0.0001
WBC (cells/mm3 ) 5200 (1800–14900) 5900 (3500–10600) 5800 (3900–12400) 0.07
Platelet count (104/mm3 ) 13.2 (2.8-30.9) 25.3 (1.8-42.1) 17.3 (8.7-44.3) 0
Prothrombin time (%) 83 (38–100) 95 (74–100) 77 (45–97) 0.01
α-fetoprotein (ng/ml) 22 (1.9-59597) 77 (2–138011) 144 (1.7-280600) 0.05
Child-Pugh grade (A/B/C) 91/26/2 10/1/0 6/10/4 <0.0001
CLIP score (0/1/2/3≧) 41/43/24/11 3/0/3/5 0/7/1/12 <0.0001
JIS score (0/1/2/3≧) 18/43/41/17 0/4/3/4 0/1/6/13 <0.0001
BCLC score (0/A/B/C,D) 18/61/31/9 0/4/2/5 0/6/2/12 <0.0001
Tumor stage (І,ІІ,ІІІ,ІV) 21/52/41/5 0/4/3/4 1/4/4/11 <0.0001
Maximal tumor diameter (mm) 30 (7–200) 110 (40–150) 50 (10–130) <0.0001
Tumor number (solitary/multiple) 66/53 6/5 5/15 0.04
Vascular invasion (absent/present) 114/5 8/3 13/7 <0.0001
Extrahepatic metastasis (absent/present) 117/2 10/1 17/3 0.01
Abbreviaions: HBsAg = hepatitis B surface antigen; HCVAb = hepatitis C antibody; AST = aspartate aminotransferase; ALT = alanine aminotransferase.
CRP = C-reactive protein; WBC = white blood cell count; ICG = indocyanine green dye retention rate at 15 minutes; CLIP = Cancer of the Liver Italian Program.
JIS = Japan Integrated Staging score; BCLC = Barcelona Clinic Liver Cancer; GPS = Glasgow Prognostic Score.
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diovascular disease (n = 2, 2.7%), cerebrovascular dis-
ease (n = 2, 2.7%), sepsis (n = 1, 1.4%), and pneumonia
(n = 1, 1.4%). The 1-year, 3-year, 5-year overall survival
rates were 74.1%, 53.3%, and 28.4%, respectively. The 1-
year, 3-year, 5-year overall survival rates in the curative
treatment group were 95.9%, 71.3%, and 41.4%, respect-
ively. The 1-year, 3-year, 5-year overall survival rates in
the non-curative treatment group were 54.9%, 34.7%,
and 14.8%, respectively.
The comparison of overall survival according to the six
staging systems is shown in Figure 2a ~ f. A significant dif-
ference in overall survival was found across all staging sys-
tems (P<0.0001 in all systems). However, no significant
difference in survival was found between mGPS 1 versus 2
(P=0.189), CLIP score 0 versus 1 (P=0.133), CLIP score 3
versus 4 (P=0.281), CLIP score 5 versus 6 (P=0.074), JIS
score 0 versus 1 (P=0.082), BCLC C versus D (P=0.083),
and TNM stage Іversus ІІ(P=0.171). Among the 6 staging
systems, only GPS demonstrated significant differences
in overall survival between all adjacent strata (P<0.05 in
all strata).Table 3 showed results of the linear trend χ2 test and −2
log likelihood for each staging system. In all patients, the
CLIP had the highest prognostic power compared to other
staging systems in terms of homogeneity and discrimin-
atory ability (linear trend χ2 test, 109.31; -2 log likelihood,
545.361). Among patients in the curative treatment group,
GPS had the highest prognostic power among all staging
systems (linear trend χ2 test, 16.33; -2 log likelihood,
169.3).
To assess the discrimination ability of each staging sys-
tems, the ROC curves were constructed for survival status
at 6-month, 12-month, 18month, and 24-month of follow-
up, and the areas under the ROC curve (AUC) were com-
pared (Table 4, Figure 3a ~ d). The CLIP had the highest
AUC value among 6 staging systems except for the 12-
month value. GPS consistently showed higher AUC values
compared with mGPS at each follow-up interval.
Prognostic factors
On univariate analysis, AST (P<0.0001), total serum biliru-
bin (P<0.0001), albumin (P<0.0001), pretreatment serum
CRP level (P<0.0001), Plt (P=0.041), AFP (P<0.0001), GPS
Figure 2 Comparison of cumulative survival according to scoring systems, GPS (a), mGPS (b), CLIP (c), JIS (d), BCLC (e), and TNM (f).
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score (P<0.0001), BCLC score (P<0.0001), TNM stage
(P<0.0001), maximal tumor diameter (P<0.0001), mul-
tiple nodules (P<0.0001), vascular invasion (P<0.0001)
and extrahepatic metastasis (P=0.001) were associated
with the overall survival (Table 5).
Due to the correlation between CRP, albumin and GPS
and between GPS and mGPS, variables (AST, total serum
bilirubin, Plt, AFP, GPS, CLIP score, JIS score, BCLC score,
TNM stage, maximal tumor diameter, multiple nodules,
vascular invasion and extrahepatic metastasis) were tested
in multivariate analysis. Multivariate analysis revealed that
only GPS (HR 1.773, 95%CI 1.239-2.539, P=0.002) and
CLIP score (HR 2.243, 95%CI1.784-2.820, P<0.0001) were
independently associated with overall survival (Table 5).
In the curative treatment group, multivariate analysis
revealed that GPS (HR 2.068, 95%CI 1.2-3.564, P=0.009)
and CLIP score (HR 1.74, 95%CI 1.019-2.971, P= 0.042)
were independently associated with overall survival. In
the non- curative treatment group, multivariate analysis
revealed that total serum bilirubin (HR 1.348, 95%CI
1.02-1.78, P=0.036) and CLIP score (HR 1.962, 95%CI1.456-2.645, P <0.0001) were independently associated
with overall survival.
When GPS was combined to the CLIP score to form
a new prognostic system, named by the authors as
inflammation-based CLIP, the new system provided
better prognostic accuracy with linear trend χ2 test
115.129, -2 log likelihood 539.132, and the area under
the ROC 0.869 at 6-month, 0.897 at 12-month, 0.865
at 18month, and 0.862 at 24-month.
Discussion
In the present study, we have demonstrated that GPS,
an inflammation-based prognostic score, is associated
with tumor progression and reduced liver function and
can be considered an independent marker of poor prog-
nosis in patients with HCC notwithstanding the disease
stage and/or liver functional status along with the CLIP
score. Moreover, GPS proved to be more suitable than
mGPS in patients with HCC with regard to its discrim-
inating ability and the monotonicity of gradients.
Links between cancer and inflammation were first estab-
lished in the nineteenth century and that were based on
Table 3 Prognostic ability of each staging system
Patients linear trend χ2 test −2 log likelihood P-value
All patients (n = 150)
GPS 53.761 588.797 <0.0001
mGPS 46.707 601.175 <0.0001
CLIP 109.309 545.36 <0.0001
JIS 64.461 570.82 <0.0001
BCLC 61.89 577.75 <0.0001
TNM 41.6 589.84 <0.0001
Curative treatment group (n = 77)
GPS 16.33 169.300 <0.0001
mGPS 5.07 177.93 0.03
CLIP 11.28 171.76 0
JIS 9.68 172.22 0
BCLC N/O N/O 0.08
TNM N/O N/O 0.09
Non-curative treatment group (n = 73)
GPS 23.71 322.27 <0.0001
mGPS 28.815 322.579 <0.0001
CLIP 29.480 311.68 <0.0001
JIS 16.72 326.370 <0.0001
BCLC 20.98 321.9 <0.0001
TNM 16.42 326.7 <0.0001
Abbreviations: GPS = Glasgow Prognostic Score; mGPS =modified Glasgow Prognostic Score;
CLIP = the Cancer of the Liver Italian Program; JIS = the Japan Integrated Staging score;
BCLC = the Barcelona Clinic Liver Cancer; TNM = tumor nodes metastasis classification; N/O = not obtained.
Kinoshita et al. BMC Cancer 2013, 13:52 Page 7 of 11
http://www.biomedcentral.com/1471-2407/13/52observations that tumors often arose at sites of chronic
inflammation and that inflammatory cells are present in
biopsied samples collected from tumor tissues. Today, it
is well known that cancer promotes release of proin-
flammatory cytokines from tumor cells. The cytokines
interact with immunovascular system and facilitate can-
cer growth, invasion, and metastasis [23,24].
Recent studies have shown that elevated serum CRP
levels may be associated with tumor size, distant metasta-
sis, vascular invasion, lymph node metastasis and tumor
recurrence, resulting in poor prognosis in patients with
various cancers, including HCC [16,25].
It has been also reported that serum albumin partici-
pate in systemic inflammatory response and that decline
of its serum level is a poor prognostic factor for long-
term survival in patients with various cancers [8,19].
Based on these reports, GPS, incorporating CRP and
serum albumin levels, may reflect both presence of the
systemic inflammatory response (CRP), and the progres-
sive nutritional decline (albumin) in patients with can-
cers, resulting in poor survival outcome [20].
Consistent with the Ishizuka’s report [14], our study
demonstrates that an elevated GPS is associated with
factors of tumor progression such as: maximal tumordiameter, tumor number, vascular invasion, extra hepatic
metastasis, higher CLIP scores, higher JIS scores, higher
BCLC scores and higher TNM classification grade. In
addition, our data show that an elevated GPS is also
associated with factors indicating reduced liver function
such as higher T-Bil, lower albumin, higher ICG and
higher Child-Pugh scores. This is partly because, unlike
in the Ishizuka’s report, in our study we enrolled patients
not eligible for surgical resection: with more advanced
stages of the disease and reduced liver function.
Although significant differences in overall survival were
found across all staging systems, such differences were not
observed between mGPS 1 versus 2, CLIP score 0 versus 1,
CLIP score 3 versus 4, CLIP score 5 versus 6, JIS score 0
versus 1, BCLC C versus D, and TNM grade Іversus ІІ,
suggesting poorer discrimination ability in early and
advanced stages of the disease. Only GPS demonstrated
significant differences in overall survival between all
adjacent strata, indicating that GPS could discriminate
between early and advanced stages of the disease.
Linear trend χ2 test and −2 log likelihood calculated
using the Cox model showed that GPS has fairly good
ability of discriminating the survival of patients in differ-
ent HCC stages and has greater homogeneity of survival
Table 4 Comparison of the area under the curve between
each scoring system at different follow-up intervals
Period AUC 95% CI P-value
6-month
GPS 0.768 0.655-0.882 <0.0001
mGPS 0.734 0.604-0.864 <0.0001
CLIP 0.871 0.779-0.963 <0.0001
JIS 0.837 0.752-0.922 <0.0001
BCLC 0.85 0.773-0.935 <0.0001
TNM 0.84 0.753-0.921 <0.0001
12-month
GPS 0.79 0.699-0.876 <0.0001
mGPS 0.75 0.650-0.855 <0.0001
CLIP 0.88 0.804-0.948 <0.0001
JIS 0.86 0.794-0.924 <0.0001
BCLC 0.88 0.813-0.946 <0.0001
TNM 0.84 0.771-0.918 <0.0001
18-month
GPS 0.78 0.690-0.864 <0.0001
mGPS 0.710 0.690-0.810 <0.0001
CLIP 0.842 0.768-0.916 <0.0001
JIS 0.83 0.753-0.901 <0.0001
BCLC 0.83 0.753-0.905 <0.0001
TNM 0.79 0.699-0.871 <0.0001
24-month
GPS 0.76 0.667-0.848 <0.0001
mGPS 0.7 0.595-0.795 <0.0001
CLIP 0.84 0.770-0.918 <0.0001
JIS 0.8 0.723-0.882 <0.0001
BCLC 0.800 0.719-0.881 <0.0001
TNM 0.76 0.675-0.852 <0.0001
Abbreviations: AUC = are under the receiver operating curve; 95% CI = 95%
confidence interval;
GPS = Glasgow Prognostic Score; mGPS =modified Glasgow Prognostic Score;
CLIP = Cancer of the Liver Italian Program; JIS = Japan Integrated Staging score;
BCLC = Barcelona Clinic Liver Cancer; TNM = tumor nodes
metastasis classification.
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curative treatment group, suggesting that it can provide
better prognostic power than other scoring systems in
the setting of curative treatment.
On multivariate analysis, GPS was independently asso-
ciated with overall survival along with the CLIP score,
which is consistent with the Ishizuka’s report [14]. How-
ever, our results indicate that GPS is an independent
marker of poor prognosis in patients with HCC in vari-
ous stages of disease and different liver functional sta-
tuses. By contrast, JIS, BCLC, and TNM were not found
to be independent poor prognostic factors. A scoring
system should be simple and easy to apply for prognosisprediction before treatment is initiated. In this regard,
GPS can be a useful tool for prognostication and stratifica-
tion of patients with HCC, because being based on only 2
laboratory data, CRP and albumin, it is conventionally
available without additional imaging techniques or histo-
logical examinations before commencing treatment [7].
The Cox model and AUC analysis showed GPS is more
suitable than mGPS for patients with HCC with regard to
discriminating ability and the monotonicity of gradients.
Recently, in a Glasgow Inflammation Outcome Study,
Proctor et al. have shown that mGPS was a powerful prog-
nostic factor independent of tumor site in patients with
cancer and was superior to GPS in the greater consistency
and more general use [12]. Their observations were based
on the results that a low albumin concentration alone was
uncommon (<10% of all patients) and was not significantly
associated with cancer-specific survival in many cancers
including hepatopancreaticobiliary cancer (P = 0.209). How-
ever, our study included 38 (25.3%) patients with low albu-
min concentration alone. Furthermore, serum albumin is
one of the components of the Child-Pugh Classification
and hypoalbuminemia has been reported as an independent
poor prognostic factor in patients with HCC [26]. More-
over, in the Glasgow Inflammation Outcome Study, hepato-
pancreatico-biliary cancer included pancreatic and biliary
tract cancers besides HCC. Therefore, we speculate that
GPS is more suitable than mGPS for patients with HCC.
A number of scoring systems for HCC have been pro-
posed to date. However, controversy remains about which
system is best at predicting survival of HCC patients.
Characteristics of tumor-related variables, the relative
score weighted for each variable, preferred treatment
modality in different centers, the numbers of analyzed
patients, and the etiology of liver diseases could contrib-
ute to this controversy [27]. In the current study, the
CLIP system proved to be the best prognostic model
for HCC with regard to discrimination ability and the
monotonicity of gradients. This result is consistent with
a previous study with HCC patients undergoing palliative
TACE and another study with advanced HCC patients
[2,26]. The CLIP system was originally derived from unse-
lected patient population and the majority of them had
received non-surgical treatment [4]. Therefore, it is gener-
ally accepted that the CLIP system may be more suitable
for predicting the survival of HCC patients who receive
non-surgical treatments than BCLC system or JIS system
[26,28]. In our study, many patients (n = 141, 94%) were
treated non-surgically, which may be an important reason
why the CLIP was superior to the BCLC or the JIS in pre-
dicting survival. However, a recent study from Taiwan has
demonstrated that the CLIP system was the best prognos-
tic model for HCC in terms of prognostic stratification for
patients from early to advanced cancer stage irrespectively
with curative or non-curative treatments [27]. This result
Figure 3 Comparisons of the area under the receiver operating curve for survival status between scoring systems at 6 month (a), 12 month
(b), 18 month (c), and 24 month (d).
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highly stable and is independent of the treatment strategy.
When GPS was combined to the CLIP system to form a
new prognostic system, named inflammation-based CLIP
provided even better prognostic accuracy than GPS alone,
suggesting that addition of GPS could improve the dis-
criminatory ability of the CLIP system.
The current study has some limitations. First, it was a
retrospective, small sample size, single-center study. Sec-
ond, the majority of patients enrolled were treated non-surgically. Our results may not be applicable to surgically
oriented centers or high volume centers with frequently
performed liver transplantations. Third, the therapeutic
effects of each treatment method were not included into
prognostic factors’ evaluation. Since many patients received
multiple treatment sessions due to tumor recurrence
during their follow-up periods (tumor progression and
worsening liver functional reserve), it was difficult to
evaluate all therapeutic effects as prognostic factors in this
patient population. Fourth, there may be the potential
Table 5 Prognostic factors for overall survival in patients with HCC
Univariate analysis Multivariate analysis












Child-Pugh grade (A/B/C) <0.0001
GPS (0/1/2) <0.0001 1.773 (1.239-2.539) 0.002
mGPS (0/1/2) <0.0001
CLIP score (0/1/2/3/4/5/6) <0.0001 2.243 (1.784-2.820) <0.0001
JIS score (0/1/2/3/4/5) <0.0001
BCLC score (0/A/B/C/D) <0.0001
tumour stage (І/ІІ/ІІІ/ІV) <0.0001
Maximal tumour diameter (mm) <0.0001
tumour number (solitary/multiple) <0.0001
Vascular invasion (absent/present) <0.0001
Extrahepatic metastasis (absent/prsent) 0
Univariate and multivariate analysis.
Abbreviaions: AST = aspartate aminotransferase; ALT = alanine aminotransferase; CRP = C-reactive protein;WBC = white blood cell count;
CLIP = Cancer of the Liver Italian Program; JIS = Japan Integrated Staging score; BCLC = Barcelona Clinic Liver Cancer;
GPS = Glasgow Prognostic Score; mGPS =modified GPS.
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tion. As progressive HCC patients would have poor liver
function and reduced albumin, GPS in this group of pa-
tient is no longer only a marker of inflammation but also a
marker of poorer liver function. However, Cervoni et al.
have demonstrated that a systemic inflammation response,
as evidenced by an elevated CRP concentration, is asso-
ciated with poor survival in Child Pugh score > B8 cir-
rhotic patients independently of Model of End Stage Liver
Disease [29]. We also have shown that CRP is an inde-
pendent marker of poor prognosis in patients with HCC,
irrespective of tumor stage and liver function [16].Conclusion
Our study demonstrated that GPS is associated with
tumor progression and reduced liver function and can
be considered as an independent marker of poor prog-
nosis in patients with HCC in various stages of disease
and different liver functional status along with the CLIP
score. GPS is more suitable than mGPS for patients withHCC with regard to discriminating ability and the mono-
tonicity of gradients.
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